Testosterone injections vs. gels for women: what the evidence says

What did @alixawinn actually say?

Here's the awkward part: the transcript and the caption are two completely different things. The actual spoken words in this video are song lyrics, something about putting your best face on and going out with a bang. There is no medical content in the transcript at all. So the claims being circulated under this video come entirely from the caption, not from anything @alixawinn said on camera.

The caption makes three specific claims: that injections offer "more consistent dosing" than gels or creams, that they produce "stronger symptom relief" across energy, mood, sex drive, and muscle tone, and that there's "no risk of rubbing off on you." Those are the claims worth examining, even if they weren't actually spoken aloud.

Does the science back this up?

Partially, yes, but the details matter a lot more than a TikTok caption can handle. Testosterone injections do produce measurable, predictable serum levels in a way that transdermal application often does not. But "stronger symptom relief" is a much harder claim to defend, and the caption oversimplifies a genuinely complicated pharmacokinetic picture.

A 2019 review by Davis et al. in The Lancet Diabetes and Endocrinology confirmed that testosterone therapy in women can improve sexual function, mood, and energy, but found no formulation was definitively superior for symptom outcomes. Absorption variability with gels is real: a 2014 study by Wierman et al. in the Journal of Clinical Endocrinology and Metabolism noted that transdermal testosterone in women shows significant inter-individual variability. Injections do sidestep the absorption guessing game. But injection-related peaks and troughs, meaning supraphysiologic spikes shortly after injection followed by drop-off, are a documented concern that the caption skips entirely.

What did they get wrong (or right)?

The transfer risk point is essentially correct. Testosterone gels carry real documented risk of skin-to-skin transfer to partners, children, and pets. The FDA has issued warnings on this. Injections eliminate that vector entirely. Credit where it's due.

The "more consistent dosing" claim is defensible but nuanced. Yes, you know exactly what dose entered the body. But injectable testosterone in women typically creates a peak-trough cycle that gel advocates would argue is less physiologically consistent than a daily transdermal application, even accounting for absorption variability. Neither is a clean win.

"Stronger symptom relief" is where the caption goes off the rails. There is no robust head-to-head trial in women showing injections outperform gels on symptom endpoints. The claim appears to be based on clinical intuition or anecdote, not controlled evidence. Saying injections are "often a game-changer" over other methods is a preference statement dressed up as a fact, and that's worth flagging plainly.

What should you actually know?

Testosterone therapy for women is not FDA-approved in the United States for any indication, full stop. Clinicians who prescribe it are doing so off-label, typically for hypoactive sexual desire disorder or symptoms of androgen insufficiency. That doesn't make it wrong, but it means the evidence base is thinner than the confident TikTok tone implies.

Formulation choice in women's TRT involves real trade-offs. Injections bring predictable absorption and zero transfer risk, but require clinic visits or self-injection and carry peak-trough variability. Gels and creams offer daily dosing flexibility but have absorption unpredictability and transfer concerns. Pellets have their own insertion risks and no dose adjustment capability once implanted. A 2021 position statement from the International Society for the Study of Women's Sexual Health noted that no single delivery method has demonstrated superiority across all outcomes.

Anyone considering testosterone therapy should be working with a licensed clinician who monitors serum levels, not making decisions based on caption bullet points.

The bottom line

The transfer risk point is solid. The consistent dosing argument is reasonable with caveats. The "stronger symptom relief" claim is unsupported by comparative trial data and should have been framed as a hypothesis or clinical preference, not a fact. The bigger issue is that the actual video contains no medical content whatsoever, so these claims exist only as text overlaid on a dancing-and-singing clip, which should probably factor into how much weight any viewer gives them.